Loading clinical trials...
Loading clinical trials...
Phase 2 Window of Opportunity Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors
Conditions
Interventions
Pemigatinib
Locations
6
United States
Sibley Memorial Hospital
Washington D.C., District of Columbia, United States
Johns Hopkins School of Medicine - Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, United States
Associated Medical Professionals Urology
Syracuse, New York, United States
Midlantic Urology
Bala-Cynwyd, Pennsylvania, United States
Keystone Urology
Lancaster, Pennsylvania, United States
Carolina Urologic Research Center
Myrtle Beach, South Carolina, United States
Start Date
October 2, 2020
Primary Completion Date
September 30, 2025
Completion Date
September 30, 2025
Last Updated
October 3, 2025
NCT00026884
NCT04235764
NCT03375307
NCT07061964
NCT07050771
NCT04585750
Lead Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions